Every Form 4 that Indaptus Therapeutics, Inc. (INDP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow INDP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INDP filings page.
Indaptus Therapeutics director David E. Lazar sold a large block of the company’s convertible preferred stock. On March 23, 2026, he completed a Securities Purchase Agreement under which he sold all 700,000 shares of Series AAA Preferred Stock, which were convertible into 105,000,000 shares of common stock, and 196,800 shares of Series AA Preferred Stock, which were convertible into 3,936,000 shares of common stock. Following this transaction, he retained 103,200 shares of Series AA Preferred Stock, convertible into 2,064,000 shares of common stock. Both the Series AA and Series AAA Preferred Stock are perpetual and convertible at the holder’s option for no additional consideration.
Jabbour Jerome D reported acquisition or exercise transactions in this Form 4 filing.
Indaptus Therapeutics director receives stock option grant. Indaptus Therapeutics, Inc. granted director Jerome D. Jabbour options to buy 25,000 shares of common stock under its non-employee director compensation program. These options vest over three years in equal quarterly installments, conditioned on his continued service on the board.
Indaptus Therapeutics Co-Chief Executive Officer and director Jeffrey Meckler reported derivative warrant transactions tied to a board-approved repricing. On February 11, 2026, previously held warrants were disposed of back to the company and replacement warrants were acquired on a direct ownership basis.
The transactions cover several warrant series exercisable for common stock, with the board unilaterally reducing the per-share exercise price of all affected warrants to $1.75 while leaving all other terms unchanged. Following the dispositions and matching acquisitions, Meckler directly holds new warrants for 3,033, 1,519, and 12,136 underlying shares at the revised exercise price.
The filing also notes that on June 26, 2025, Indaptus implemented a 1-for-28 reverse stock split of its common stock, and all warrant amounts in the report reflect this adjustment.
Indaptus Therapeutics director Avraham Ben-Tzvi reported new equity awards. On January 20, 2026, he received 25,000 shares of restricted common stock as compensation under a consulting agreement, and these shares vested in full immediately upon grant. Following this award, he beneficially owns 25,100 shares of Indaptus common stock, including 100 shares held in a Roth IRA.
Separately, on December 23, 2025, he was granted options to purchase 25,000 shares of Indaptus common stock under the company’s non-employee director compensation program. These stock options vest over three years in equal quarterly installments, so long as he continues to serve on the board through each vesting date.
Indaptus Therapeutics director David Natan received a new stock option grant covering 25,000 shares of common stock. The options have an exercise price of $2.69 per share and were granted on January 7, 2026 under the company’s non-employee director compensation program. The award vests over three years in equal quarterly installments starting from the grant date, as long as Natan continues to serve on the board through each vesting date. Following this grant, he beneficially holds 25,000 stock options directly.